Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA): a Prospective, Paired Diagnostic Study

NCT06867588 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT06867588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06867588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA): a Prospective, Paired Diagnostic Study
Lead sponsor
Jules Bordet Institute
Phase
Not applicable
Overall status
Recruiting
Start date
October 17, 2024
Completion date
December 31, 2026
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lesion pi-rads 3, multiparametric mri